Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 3/20 | 0.57 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | RRM1 | P23921 | 1/20 | 0.47 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22801067 | 0.88 | PHGDH (0.53) | PHGDHSCDADORA3ALKKDM4E | |
| SCHEMBL22801081 | 0.76 | FBP1 (0.48) | SCDKDM4EMEN1MAPTKMT2A | |
| SCHEMBL22801049 | 0.74 | SCD (0.51) | SCDADORA3ALKRRM1RRM2B | |
| SCHEMBL25295451 | 0.74 | LMNA (0.57) | PHGDHSCDADORA3KDM4EMEN1 | |
| SCHEMBL22801025 | 0.74 | KDM4E (0.56) | SCDADORA3RRM1RRM2BKDM4E | |
| SCHEMBL22801093 | 0.73 | KDM4E (0.52) | PHGDHSCDADORA3ALKRRM1 | |
| SCHEMBL25769824 | 0.73 | SCD (0.67) | PHGDHSCDADORA3NAMPTPARP1 | |
| SCHEMBL24107788 | 0.72 | PHGDH (0.71) | PHGDHSCDADORA3PARP1KDM4E | |
| SCHEMBL4741397 | 0.72 | RAB9A (0.56) | PHGDHSCDADORA3RRM1RRM2B | |
| SCHEMBL4746841 | 0.72 | ALDH1A1 (0.63) | PHGDHSCDADORA3RRM1RRM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399264-A1 | 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS | NATIONAL INSTITUTES OF HEALTH | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399264-A1 | 4-SUBSTITUTED-2-THIAZOLE AMIDES AS ANTIVIRAL AGENTS | MAVS, ZC3HAV1, EIF2AK2 | PHGDH 2570/4885SCD 4612/4885ADORA3 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.